EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australia
SAB Biotherapeutics Inc (NASDAQ: SABS) announced that the first HUMAN trial participants (Fully HUman anti-thymocyte biologic in a first-in-MAN clinical study) have been dosed in Australia. This Phase 1 randomized, double-blind, placebo-controlled, single-ascending dose, adaptive design clinical study was designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous SAB-142 in healthy volunteers and participants with type-1 diabetes (T1D). SAB-142 is a first-
Source: yahoo.com